secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-01-23T23:59:59+00:00
Accession:  0001437749-24-001909
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics appoints Alvin Shih, M.D. to board of directors
------------------------------------------------------------------

- Dr. Alvin Shih appointed as Class III director effective January 20, 2024.
- Shih has rare disease experience, former COO of Pfizer's Rare Disease Research Unit.
- Initial option grant of 58,800 shares vesting over 3 years, annual retainer $40,000.
- Shih will receive additional option of 39,200 shares annually while serving on board.
- No family relationships or transactions requiring disclosure under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924001909/0001437749-24-001909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924001909/zvra20240112_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-001909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer